Portland, OR, Sept. 12, 2019 (GLOBE NEWSWIRE) -- According to a report published by Allied Market Research, the global acute lymphocytic/lymphoblastic leukemia therapeutics market was accounted for $2.33 billion in 2018 and is projected to reach $3.53 billion by 2026, registering a CAGR of 5.3% from 2019 to 2026. The research offers a vast analysis of major segments, changing market trends, top pocket investors, drivers and opportunities, and competitive scenarios.
Download Sample Report https://www.alliedmarketresearch.com/request-sample/564
Surge in the number of new product approvals and rise in the rate of acute lymphoblastic leukemia drive the growth of global acute lymphocytic/lymphoblastic leukemia therapeutics market. However, expiry of blockbuster drugs and certain side effects of the treatment restrain the market growth. Moreover, increasing number of clinical trials is estimated to provide lucrative opportunities to the acute lymphocytic/lymphoblastic leukemia therapeutics market.
Based on region, North America held the largest revenue share in 2018, contributing to nearly half of the total market share. The region is projected to continue its highest position throughout the forecast period. However, Asia Pacific region would grow at the highest CAGR of 6.3% during the forecast period.
On the basis of type, the pediatrics segment held the largest share in 2018, contributing to more than half of the total share. The segment is expected to continue its position throughout the estimated period. Furthermore, this segment would grow at the fastest CAGR of 5.7% during the forecast period.
Based on type of drugs, the hyper-CVAD regimen segment held the major market share in 2018, accounting for nearly one-third of the total market share. This region would continue its leadership position throughout the forecast period. Moreover, the targeted drugs & immunotherapy segment would grow at the highest CAGR of 6.5% during the forecast period.
The key players in the 3D printing market include Bristol-Myers Squibb Company, Rare Disease Therapeutics, Erytech Pharma, Inc., Leadiant Biosciences, Inc., (Sigma-Tau Pharmaceuticals Inc.), Novartis AG, Sanofi, Pfizer, Inc, Takeda Pharmaceutical Company Limited, and Spectrum Pharmaceuticals, Inc.
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.